Navigation Links
Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
Date:2/24/2009

SAN FRANCISCO, Feb. 24 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast of a slide presentation on Wednesday, February 25, at 4:30 p.m. Eastern Time to discuss new efficacy and safety data from the ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer patients.

Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, will participate in the teleconference. He will discuss the new MDV3100 data, as well as recent research regarding the association between changes in the number of circulating tumor cells (CTCs) and the prediction of survival and response to treatment in patients with advanced prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Wednesday, February 25, at 4:30 p.m. Eastern Time by telephone, please dial 877-719-9810 from the U.S. or +1-719-325-4785 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A slide presentation that will accompany the teleconference can be accessed via the Web by accessing the webcast and will also be posted as a PDF next to the event listing in the Investor section of the Medivation website. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
5. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
6. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
7. drugstore.com, inc. to Present at the Upcoming Jefferies 5th Annual Internet & Media Conference
8. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference
9. Case Management Society of America Hosting Conference on Health Care Case Management
10. Service Corporation International Announces Schedule for Its Fourth Quarter 2008 Earnings Release and Conference Call
11. Nationwide to Present at Citigroup Global Property CEO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... The producers of ... of American businesses. , The increasingly modern world of instantaneous consumption proves very ... non-renewable energy sources such as oil and coal, which pollutes our air, water, and ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
(Date:2/12/2016)... ... , ... The law firm of Morrow, Morrow, Ryan & Bassett is offering ... scholarships is to encourage applicants to pursue a degree in their field of study ... , “We have available jobs in St. Landry and Evangeline Parishes that can ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, ... ... in Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, ... burner issue in the life cycle of pharmaceutical products, garnering increased attention from ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... Feb. 11, 2016 Potrero Medical, Inc., the developer ... announce the appointment of George M. Rapier, III , ... Antonio, TX , WellMed is one of the nation,s ... and HMO members in Texas and ... out of his own internal medicine practice, he has been ...
(Date:2/11/2016)... Ga. , Feb. 11, 2016  MiMedx Group, ... company utilizing human amniotic membrane and other birth tissues, ... platforms to develop and market advanced products and therapies, ... Capital Markets, 2016 Global Healthcare Conference in ... Chairman and CEO, Michael J. Senken , Chief ...
Breaking Medicine Technology: